Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX-0,22 % EUR/USD-0,19 % Gold+0,29 % Öl (Brent)-2,66 %

Biotech Brief Researchers Looking at New Bundled Treatment Options for Leukemia

Nachrichtenquelle: PR Newswire (engl.)
10.07.2019, 14:45  |  377   |   | News Commentary

PALM BEACH, Florida, July 10, 2019 /PRNewswire/ -- The American Cancer Society estimates that in 2019 there will be about 61,780 new cases of leukemia and 22,840 deaths from leukemia and 21,450 new cases of acute myeloid leukemia (AML). Most will be in adults. About 10,920 deaths from AML… again almost all will be in adults. AML is generally a disease of older people and is uncommon before the age of 45. The average age of people when they are first diagnosed with AML is about 68… but AML can also occur in children as well. But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions…. (and)… There has been great progress in understanding how changes in the DNA (genes) inside normal bone marrow cells can cause them to develop into leukemia cells. A greater understanding of the gene changes that often occur in AML is providing insight into why these cells become abnormal. As researchers have found more of these changes, it is becoming clear that there are many types of AML. Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful. Doctors are now learning how to use these changes to help them determine a person's outlook and if they should receive more or less intensive treatment. Perhaps even more important, this knowledge is now being used to help develop newer targeted therapies against AML."    Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ:MBRX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Endo International plc (NASDAQ: ENDP), Altimmune, Inc. (NASDAQ: ALT), Amarin Corporation plc (NASDAQ: AMRN).

Chemotherapy is the main treatment for most types of AML but: "… Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo. They are also looking at combining chemo with a number of newer types of drugs to see if this might work better… Newer targeted drugs that specifically attack some of the gene changes seen in AML cells are now becoming an important part of treatment for some people with AML."

Diesen Artikel teilen
Seite 1 von 4
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten

Aus der Community
LUS Wikifolio-Index BITCOIN performance Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index BITCOIN, ETHEREUM & GOLD Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index Sehr bekannte Kryptowaehrung Index Zertifikat Open-End (LASW)
Chart: arniarni